Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...
Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses.
The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant benefit on progression-free survival among ...
A dexamethasone-sparing regimen of daratumumab and lenalidomide was safe and effective in older, frail patients with newly diagnosed multiple myeloma. Among that select group of patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results